Akeso Biopharma Inc.
850 Winter Street
About Akeso Biopharma Inc.
Akeso Biomedical is a food safety company developing new solutions for the treatment of bacterial infections using a broad-spectrum iron complex chemistry (“Fe3C”) discovered by researchers at the University of Nottingham, UK. The Company’s pipeline includes antibiotic-free feed additives to improve the health of farm animals and reduce the levels of infection by Campylobacter, Salmonella, and E. coli.
CEO: Simon Williams, PhD
COO: Jerome Meier
Please click here for Akeso Biomedical's technology.
40 articles about Akeso Biopharma Inc.
Akeso's Cadonilimab (PD-1/CTLA-4), the First Dual Immune Checkpoint Inhibitor to Treat Cancer, Approved for Marketing in China
Globally first dual immune checkpoint inhibitor bi-specific antibody approved for marketing.
Akeso releases promising data of Ivonescimab (PD-1/VEGF BsAbs, AK112) for advanced NSCLC at ASCO 2022
Akeso, Inc. released clinical details in poster presentation featuring phase Ib/II study of its Ivonescimab in advanced non-small cell lung cancer at 2022 ASCO Annual Meeting.
Akeso releases promising data of Ivonescimab (PD-1/VEGF BsAbs, AK112) combined with chemotherapy in advanced NSCLC at ASCO 2022
Akeso, Inc. released clinical details in poster discussion featuring a phase II study from Ivonescimab in combination with chemotherapy for advanced non-small cell lung cancer at 2022 ASCO Annual Meeting.
Akeso announces oral presentation featuring promising clinical data of Cadonilimab (PD-1/CTLA-4 BsAbs, AK104) for the first-line treatment of R/M cervical cancer at ASCO 2022
Akeso, Inc. released updated results of Cadonilimab combined with platinum-based chemotherapy +/- bevacizumab for the first-line treatment of recurrent/metastatic cervical cancer.
Akeso Publishes Preclinical Results of TIGIT monoclonal antibody（AK127）at the American Association for Cancer Research (AACR) 2022 Annual Meeting
Akeso, Inc. announced the publication of preclinical results of its anti-TIGIT monoclonal antibody showing potent preclinical anti-tumor activities at the American Association for Cancer Research Annual Meeting 2022.
Akeso Publishes Preclinical Results of PD-1/LAG-3 Bi-specific Antibody（AK129）at the American Association for Cancer Research (AACR) 2022 Annual Meeting
Akeso, Inc., a China-based biopharmaceutical company focusing on the development and commercialization of innovative therapeutic antibodies for Oncology & Immunology, announced the publication of preclinical results of its PD-1/LAG-3 bi-specific antibody at the American Association for Cancer Research Annual Meeting 2022.
Akeso Publishes Preclinical Results of PD-1/CD73 Bi-specific Antibody（AK131）at the American Association for Cancer Research (AACR) 2022 Annual Meeting
Akeso, Inc. announced the publication of preclinical results of its PD-1/CD73 bi-specific antibody at the American Association for Cancer Research Annual Meeting 2022.
Akeso, Inc., a China-based biopharmaceutical company focusing on the development and commercialization of innovative therapeutic antibodies for Oncology & Immunology, reported 2021 annual results.
Across a range of indications, COVID-19-related and non-COVID-19-related, there was plenty of clinical trial news last week.
Akeso Announces IND Approval from China NMPA for Phase II Clinical Trial of Cadonilimab in Combination with Docetaxel to Treat NSCLC
Akeso, Inc. announced that the CDE of China's National Medical Products Administration has approved the IND application for the initiation of the open-label, multicenter phase II trial in China using Cadonilimab in combination with Docetaxel in patients with advanced NSCLC which progressed on combination therapy of PD-1/L1 inhibitor and platinum-based doublet chemotherapy.
Akeso Announced Collaboration With Chipscreen Biosciences To Initiated A Clinical Trial Of PD-1/CTLA-4 Bi-Specific Antibody In Combination With Chiauranib For PD-(L)1 Pretreated ES-SCLC
Akeso, Inc. announced that it entered into a collaboration agreement with Shenzhen Chipscreen Biosciences Co., Ltd. to establish a clinical trial partnership to jointly conduct a Phase Ib/II clinical trial of PD-1/CTLA-4 bi-specific antibody Cadonilimab in combination with Chiauranib for the treatment of first-line platinum-based chemotherapy in combination with PD-1 inhibitor treatment regimen for extensive stage small cell lung cancer.
PD-1/VEGF Bi-Specific Antibody (AK112) Obtained Approval to Initiate a Phase II Clinical Trial for Monotherapy or Combined Chemotherapy Neoadjuvant/Adjuvant Therapy of Resectable Non-Small Cell Lung Cancer
Akeso, Inc. announces that AK112, the novel immuno-oncology drug independently developed by the Company, obtained approval from the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China to initiate a phase II clinical trial for monotherapy or combined chemotherapy neoadjuvant/adjuvant therapy of resectable non-small cell lung cancer.
New Drug Application for Cadonilimab (PD-1/CTLA-4 Bi-Specific Antibody) for the Treatment of Relapsed or Metastatic Cervical Cancer Accepted by NMPA
Akeso, Inc. (the Company, 9926.HK) announces that the National Medical Products Administration (the NMPA) of China has officially accepted the new drug application for the world's first-in-class Cadonilimab (PD-1/CTLA-4 bi-specific antibody, research and development code: AK104) for the treatment of relapsed or metastatic cervical cancer, which has received priority review.
CD47 Monoclonal Antibody (AK117) Completed Phase I Dose Escalation Trial and Obtained Approval to Initiate Clinical Trial in Combination with Azacitidine for Treatment of Acute Myeloid Leukemia
Akeso, Inc. is pleased to announce that, CD47 monoclonal antibody (AK117), a second-generation novel drug for immuno-oncology therapy independently developed by the Company, has completed phase I dose escalation trial in Australia .
Akeso, Inc. is pleased to announce that, Akeso has been awarded as "Most Honored Company" in the "2021 All-Asia Executive Team" survey published by Institutional Investor, and has been ranked top 3 in all five categories in the Healthcare & Pharmaceuticals Sector.
Akeso, Inc. announced that Penpulimab, an PD-1 monoclonal antibody drug co-developed by the Company with Sino Biopharmaceutical Limited, has submitted a Biologics License Application to the Food and Drug Administration of the United States for third-line treatment of metastatic nasopharyngeal carcinoma.
ANTI-PD-1/CTLA-4 Bi-specific Antibody (AK104) of Akeso Granted FDA Fast Track Designation for Recurrent and Metastatic Cervical Cancer
Akeso, Inc (9926.HK) - a biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of new innovative antibody drugs that are affordable to patients worldwide - today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for AK104, a novel anti-PD-1/CTLA
Akeso Appoints Prof. Bradley Monk as Lead Gynecologic Oncology Advisor and Chair of the Steering Committee
To develop its registration trial of AK104 (Bi-specific Anti-PD1/CTLA-4 Antibody) in Cervical Cancer
Akeso Biomedical Advances Technology To Reduce Foodborne Illness; Receives New Patent To Reduce Campylobacter Infections